Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway

Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma

(2012) Hung Huynh et al.   Anti-Cancer Agents in Medicinal Chemistry

Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model

(2012) Mitra Heravi et al.   ANTI-CANCER DRUGS

Sorafénib et radiothérapie dans le carcinome hépatocellulaire

(2011) N. Girard et al.   Cancer Radiotherapie

EGF Receptor Inhibition Radiosensitizes NSCLC Cells by Inducing Senescence in Cells Sustaining DNA Double-Strand Breaks

(2011) M. Wang et al.   CANCER RESEARCH

Enhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK Inhibition

(2011) M. E. Urick et al.   CLINICAL CANCER RESEARCH

MEK/ERK Inhibitor U0126 Increases the Radiosensitivity of Rhabdomyosarcoma Cells In vitro and In vivo by Downregulating Growth and DNA Repair Signals

(2011) F. Marampon et al.   MOLECULAR CANCER THERAPEUTICS

Targeted therapy of hepatocellular cancer

(2010) Piotr Jan Wysocki   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sorafenib and Radiation: A Promising Combination in Colorectal Cancer

(2010) Andrew W. Suen et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Mitogen-activated protein kinases in hepatocellular carcinoma development

(2010) Lihua Min et al.   SEMINARS IN CANCER BIOLOGY

Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis

(2010) Morris Sherman   SEMINARS IN LIVER DISEASE

Review article: the management of hepatocellular carcinoma

(2009) R. CABRERA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase

(2009) E. J. Chung et al.   CLINICAL CANCER RESEARCH

Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems

(2009) Matthew Hennig et al.   HEPATOLOGY

Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK

(2009) Maria J. Sambade et al.   RADIOTHERAPY AND ONCOLOGY

Current management strategy of hepatocellular carcinoma

(2009) Bernardino Rampone et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

(2008) Y. Dai et al.   BLOOD

Conformal radiotherapy for hepatocellular carcinoma

(2008) R.V. Tse et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo

(2008) A Bessard et al.   ONCOGENE